Developed by CDx Diagnostics, WATS3D® is an advanced diagnostic platform that addresses the major inadequacies inherent in random forceps biopsy of the esophagus; combining the medical advances of superior sampling and advanced 3D imaging that leverages artificial intelligence to sharply increase more effective detection of both BE and ED.
WATS3D is included in the New ASGE Practice Guideline for both the Screening and Surveillance of Barrett’s Esophagus.
In just a few minutes, endoscopists can easily obtain a wide area, full-thickness transepithelial specimen for computer-assisted 3D laboratory analysis for diagnosis by any WATS3D certified pathologist.
Critically, the computer synthesized WATS3D image presents an in vivo, en face view of the gland to the pathologist — allowing for a definitive diagnosis of dysplasia in cases that would otherwise be reported as “indefinite.”
Additionally, the WATS3D computer-assisted technology yields sharply higher inter-observer agreement among pathologists compared with FB. This is because the WATS3D neural network highlights the most suspicious areas on this computer synthesized image areas for consistent pathologist review. In large multicenter clinical trials, WATS3D has been found to significantly increase the detection rate of both Barrett’s esophagus and esophageal dysplasia.
CDx Diagnostics’ mission is to provide clinicians with easily implemented, cost effective tools to preempt cancer through enhanced detection of precancerous cellular changes. This is accomplished by a proprietary diagnostic platform that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous change earlier and more reliably than prior methods.
2 Executive Blvd.
Suffern, NY 10901